Glaxo Takes Another Shot At China: A Joint Venture to Make And Sell Its Priorix Vaccine
This article was originally published in PharmAsia News
Executive Summary
In its second vaccine-related collaboration with a Chinese company this year, GlaxoSmithKline announced on Oct. 6 that it is teaming up with Jiangsu Walvax Biotech to develop and manufacture pediatric vaccines in the fast-growing Asian nation
You may also be interested in...
GSK Channels More Money Into Vaccine Venture With China's Neptunus As Earnings Sink In The West
BEIJING - Despite posting a sizeable loss in earnings for the second quarter of this year, GlaxoSmithKline is pumping new funds into its recently established joint venture in southern China in a move aimed at profiting from China's healthy economic growth despite the financial ailments that have plagued the Western world
GSK Channels More Money Into Vaccine Venture With China's Neptunus As Earnings Sink In The West
BEIJING - Despite posting a sizeable loss in earnings for the second quarter of this year, GlaxoSmithKline is pumping new funds into its recently established joint venture in southern China in a move aimed at profiting from China's healthy economic growth despite the financial ailments that have plagued the Western world
Merck Teams Up With Sinopharm On Vaccines As It Gears Up For Gardasil Approval In China
HONG KONG - U.S.-based Merck and China's Sinopharm plan to work together to develop vaccines in China under a preliminary deal that could ultimately see Sinopharm marketing more of the pharmaceutical giant's products in Asia's most populous nation